Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Prospective nonrandomized phase I study
The purpose of this study is to determine safety and efficacy of zileuton when added to
dasatinib in patients with chronic myelogenous leukemia (CML).